DT-7012

DRUG3 trials

Sponsors

Domain Therapeutics Australia Pty Ltd, Assistance Publique - Hôpitaux de Paris, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Advanced Solid TumorsCutaneous T Cell Lymphoma (CTCL)Dedifferentiated Liposarcoma (DDLPS)Mycosis FungoidesSezary SyndromeUndifferentiated Pleomorphic Sarcoma (UPS)

Early Phase 1

A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Not yet recruitingNCT07213882

Assistance Publique - Hôpitaux de ParisCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome

Start: 2026-01-01End: 2028-08-01Target: 30Updated: 2025-10-09

Phase 1

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

RecruitingNCT06819735

Domain Therapeutics Australia Pty LtdAdvanced Solid Tumors

Start: 2025-06-25End: 2028-01-01Target: 125Updated: 2026-05-06

Phase 2

Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma

Not yet recruitingNCT07802652

Gustave Roussy, Cancer Campus, Grand ParisDedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS)

Start: 2027-02-01End: 2031-11-01Target: 80Updated: 2026-09-15

Related Papers

Abstract CT285: Design and rationale of DOMISOL, a first-in-human Phase I/II study of DT-7012 (NCT06819735) in advanced solid tumors

Cancer Research2026-04-17